1	HOUSE OF REPRESENTATIVES - FLOOR VERSION
2	STATE OF OKLAHOMA
3	2nd Session of the 57th Legislature (2020)
4	COMMITTEE SUBSTITUTE
5	FOR HOUSE BILL NO. 2617 By: Echols
6	
7	
8	COMMITTEE SUBSTITUTE
9	An Act relating to pharmacy consultants; defining
10	terms; establishing that a pharmacy consultant performing pharmacy benefit management services shall
11	have a fiduciary duty to the state; requiring certain performance standards and notification; requiring
12	certain disclosure; prohibiting contract waiver of fiduciary duty; providing for codification; and
13	providing an effective date.
14	
15	
16	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
17	SECTION 1. NEW LAW A new section of law to be codified
18	in the Oklahoma Statutes as Section 360.1 of Title 59, unless there
19	is created a duplication in numbering, reads as follows:
20	A. As used in this act:
21	1. "Covered individual" means a policy holder, subscriber,
22	enrollee or other individual participating in a health benefit plan
23	offered by the state;
24	

1	2. "Entity" means a sole proprietor, general partnership,
2	limited partnership, limited liability partnership, limited
3	liability limited partnership, corporation, limited liability
4	company or any other lawfully recognized business entity;

- 3. "Fiduciary duty" means the same duties imposed by law upon a trustee of an express private trust;
- 4. "Pharmacy consultant" means any entity, including but not limited to pharmaceutical consultants, pharmacy benefits managers, and managed care organizations, that provides pharmacy benefits management services to the state through contract;
- 5. "Pharmacy benefits management services" means services provided to the state through contract, to facilitate the provision of prescription drug benefits to covered individuals within the state, including:
 - a. negotiating prices and other terms with drug manufacturers and providers,
 - b. claims processing, retail network management, and payment of claims to pharmacies for prescription drugs dispensed to covered individuals,
 - c. rebate contracting and administration,
 - d. certain patient compliance, therapeutic intervention, and generic substitution programs,
 - e. disease management programs,
 - f. formulary consultation,

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- g. developing value-based contracts analytics, or
- h. drug utilization review; and

- 6. "State" means Oklahoma Health Care Authority or the Office of Management and Enterprise Services.
- B. Any pharmacy consultant that enters into a contract with the state to perform pharmacy benefits management services shall owe a fiduciary duty to the state or the counterparty to the contract with any state governmental entity.
- C. In addition to any other fiduciary duty that may be imposed pursuant to the provisions of this act, a pharmacy consultant performing pharmacy benefits management services shall:
- 1. Perform its duties with care, skill, prudence, and diligence and in accordance with the standards of conduct applicable to a fiduciary in an enterprise of a like character and with like aims; and
- 2. Notify the state in writing of any activity, policy or practice of pharmacy benefits management services that directly or indirectly presents any conflict of interest with the duties imposed by this section.
- D. Upon request by the state, a pharmacy consultant performing pharmacy benefits management services under contract with the state shall disclose to the state all financial terms and arrangements for remuneration of any kind that apply between the pharmacy consultant performing pharmacy benefits management services and any

1	prescription drug manufacturer or labeler, including, without
2	limitation, formulary management and drug-substitution programs,
3	educational support, claims processing, and data sales fees.
4	E. Any provision of a contract between the state and a pharmacy
5	consultant that waives or limits the obligations as set forth in
6	this section is against public policy, void, and unenforceable.
7	SECTION 2. This act shall become effective November 1, 2020.
8	
9	COMMITTEE REPORT BY: COMMITTEE ON RULES, dated 03/02/2020 - DO PASS,
As Amended.	As Amended.
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	